Spyre Therapeutics officer granted 140,000 options

Spyre Therapeutics, Inc. reported a new stock option grant to an executive officer.

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. reported a new stock option grant to an executive officer. Chief Legal Officer and Corporate Secretary Heidy King-Jones received a stock option covering 140,000 shares of Spyre Therapeutics common stock on 01/09/2026.

The option has an exercise price of $30.61 per share and was reported as acquired with no cash paid for the option itself. The grant vests in equal monthly installments over four years, conditioned on her continued employment with the company at each vesting date. Following this grant, she beneficially owns 140,000 derivative securities directly in the form of this option.

Insider Trade Summary

Grant/Award: 140,000 shares

Grant/Award 1 txn

Insider King-Jones Heidy

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	140,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 140,000 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

FAQ

What did Spyre Therapeutics (SYRE) disclose in this Form 4 filing?

Spyre Therapeutics disclosed that Chief Legal Officer and Corporate Secretary Heidy King-Jones was granted a stock option for 140,000 shares of common stock on 01/09/2026.

What are the key terms of Heidy King-Jones’s stock option at Spyre Therapeutics (SYRE)?

The derivative security is a Stock Option (Right to Buy) for 140,000 shares of Spyre Therapeutics common stock with an exercise price of $30.61 per share.

How does the 140,000-share option for Spyre Therapeutics (SYRE) vest?

The option will vest in equal monthly installments over four years, subject to Heidy King-Jones’s continued employment with Spyre Therapeutics at each vesting date.

Is this Spyre Therapeutics (SYRE) Form 4 a sale or a grant of securities?

It is a grant of a derivative security, coded as transaction type A (acquired) for a stock option, not a sale of common shares.

How many Spyre Therapeutics (SYRE) derivative securities does Heidy King-Jones own after this transaction?

After the reported grant, Heidy King-Jones beneficially owns 140,000 derivative securities, all from this stock option, held in direct ownership.

Who is the reporting person in this Spyre Therapeutics (SYRE) insider filing?

The reporting person is Heidy King-Jones, an officer of Spyre Therapeutics serving as Chief Legal Officer and Corporate Secretary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/13/2026 - 09:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

King-Jones Heidy

(Last) (First) (Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.61	01/09/2026		A		140,000		(1)	01/09/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Heidy King-Jones	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.